Interní Med. 2015; 17(1): 26-27

News in the treatment of hepatitis C

prof.MUDr.Petr Husa, CSc.
Klinika infekčních chorob LF MU a FN Brno, Brno

Treatment of chronic hepatitis C is undergoing extraordinary changes in the past 4 years. Direct-Acting Antivirals (DAA) are gradually

introducing into routine clinical practice either in combination with pegylated interferon and ribavirin, or in interferon-free or even

ribavirin-free regimes. Sofosbuvir, simeprevir, and fixed combination of sofosbuvir and ledipasvir have been already approved in the

European Union and United States. Daclatasvir has been additionally approved in the European Union. The advantages of DAA are high

potency and minimum of adverse events.

Keywords: hepatitis C, pegylated interferon, ribavirin, boceprevir, telaprevir, sofosbuvir, simeprevir, daclatasvir, ledipasvir

Published: February 27, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husa P. News in the treatment of hepatitis C. Interní Med. 2015;17(1):26-27.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Urbánek P, Husa P, Šperl J, et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Dostupné na: www.ces-hep.cz nebo www.infekce.cz.
    2. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013; 58(4): 583-592. Go to original source... Go to PubMed...
    3. Poordad F, McCone J jr, Bacon BR, et al.; for SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1195-1206. Go to original source...
    4. Bacon BR, Gordon SC, Lawitz E, et al.; for HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1207-1217. Go to original source...
    5. Jacobson IM, McHutchinson JG, Dusheiko G, et al.; for ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364(25): 2405-2416. Go to original source...
    6. Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon alfa 2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid virological response: final results of Phase 3 ILLUMINATE study. Hepatology 2010; 52(S4): 401A-402A.
    7. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364(25): 2417-2428. Go to original source...
    8. EASL recommendation on treatment of hepatitis C. April 2014. Dostupné na www.easl.eu.
    9. AASLD recommendation for testing, managing, and treating hepatitis C. Dostupné na www.hcvguidelines.org.
    10. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887. Go to original source...
    11. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877. Go to original source...
    12. Sovaldi Prescribing Information. Dostupné na: www.gilead.com.
    13. U.S. Food and Drug Administration. Olysio (simeprevir) for the treatment of chronic hepatitis C in combination antiviral treatment. Dostupné na: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm377234.htm.
    14. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221. Go to original source...
    15. Ledipasvir-sofosbuvir (Harvoni) Full Prescribing Information. Dostupné na www.gilead.com.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.